netFormulary NHS
Cambridgeshire and Peterborough
Formulary
 Search
 Results

Looking for Acitretin found 12 matches

Formulary BNF Category
  Restricted Drug  Acitretin  (Neotigason) Oral retinoids for psoriasis - 13.05.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.05.02)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.06.01)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.06.01)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.06.01)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.06.01)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.06.01)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.05.01)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (08.01.05)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.06.02)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (08.01.05)
link in drug section MHRA Letters sent to healthcare professionals in June 2019: Retinoids▼ (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, and Tazarotene) - risk of teratogenicity and neuropsychiatric disorders (13.05.02)


 

netFormulary